

Scynexis Inc. (SCYX)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001178253

Scynexis Inc. SCYX; healthcare	
Grade	C  middle fifth of 371 graded peers percentile 48.1; sampling error 2.5 points; lower is stronger
Rank	179 of 371
Profitability	D  percentile 64.0
Solvency	B  percentile 31.6
Growth and financing	C  percentile 46.2
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$12.5M to \$120M assets total assets \$59.0M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active; fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Mar 4, 2026 219 days before the rescans; latest periodic filing 10-Q received Aug 10, 2026
Last close	\$4.19 2026-10-08; market equity \$41.7M
Price used in grade	None

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 4, 2026

SCYNEXIS, Inc. is dedicated to advancing innovative solutions for severe rare diseases, with our lead program in the treatment and prevention of difficult-to-treat and drug-resistant fungal infections. We are developing our proprietary antifungal platform "fungersps", a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a broad range of human fungal pathogens such as *Candida* and *Aspergillus* genera, including multidrug-resistant strains, as well as *Pneumocystis*, *Coccidioides*, *Histoplasma* and *Blastomyces* genera and most common

mucorales species.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 64.0						
Gross profitability		not computable	32.2%			latest aligned inputs end 2014-12-31; latest annual assets end 2025-12-31
Return on invested capital		not computable	9.3%			a prior annual debt, equity, and cash observation is required
Accruals ratio		(4.4%)	(6.6%)	64.0	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 1
Solvency, sleeve percentile 31.6						
Twelve-month failure probability		0.01%	0.07%	1.6	248	2026-06-30
Altman Z double-prime		(13.88)	(0.31)	67.9	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		7.04x	2.96x	25.3	839	2025-12-31
Growth and financing, sleeve percentile 46.2						
Revenue growth, three-year compound		59.4%	10.0%	10.1	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			NOPAT must exceed \$100,000
Asset growth, three years		(12.4%)	2.1%	72.0	704	2025-12-31
Net share issuance, one year		14.6%	2.5%	56.4	634	2026-03-01


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 70,091,000 USD; Altman Z is not used

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
174	Align Technology Inc. (ALGN)	46.8	C	
175	ClearPoint Neuro, Inc. (CLPT)	47.0	C	
176	Anika Therapeutics, Inc. (ANIK)	47.3	C	fortress
				balance sheet
177	Davita Inc. (DVA)	47.6	C	
178	Kymera Therapeutics, Inc. (KYMR)	47.8	C	dilution
179	Scynexis Inc. (SCYX) <	48.1	C	fortress
				balance sheet
180	Amneal Pharmaceuticals, Inc. (AMRX)	48.4	C	
181	Macrogenics Inc. (MGNX)	48.6	C	
182	Savara Inc. (SVRA)	48.9	C	short runway, fortress balance sheet
183	Biodesix Inc. (BDSX)	49.2	C	dilution
184	Evolus, Inc. (EOLS)	49.5	C	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(15.1%)	8.0%	36
Distance from 52-week high	(52.5%)	(31.4%)	25
EBIT to enterprise value	(24.3%)	(1.5%)	22
Free cash flow yield	(129.9%)	(1.0%)	4
Book value to price	1.59	0.28	94
Sales to price	0.49	0.31	65
Composite equity issuance, five years	135.1%	20.3%	84
Relative strength against the sector, log excess return	(0.38)	(0.14)	36

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$10.5M
Operating cash flow, four quarters	-\$13.3M

Months of runway	9.5
Days since last periodic filing	60 (10-Q received Aug 10, 2026)
Median daily dollar volume, 63 sessions	\$306,928

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$3.6M	2014-12-31	2015-03-30	10-K	0001178253-15-000034
2	assets	us-gaap:Assets	\$39.7M	2014-12-31	2016-03-07	10-K	0001178253-16-000144
3	operating income	us-gaap:OperatingIncomeLoss	-\$60.8M	2021-12-31	2023-03-31	10-K	0000950170-23-011138
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$36.0M	2021-12-31	2023-03-31	10-K	0000950170-23-011138
5	income tax	us-gaap:IncomeTaxExpenseBenefit	-\$3.1M	2021-12-31	2023-03-31	10-K	0000950170-23-011138
6	total debt	us-gaap:LongTermDebt	\$34.4M	2021-12-31	2023-03-31	10-K	0000950170-23-011138
7	book equity	us-gaap:StockholdersEquity	\$41.3M	2021-12-31	2024-03-28	10-K	0000950170-24-038046
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$104.5M	2021-12-31	2023-03-31	10-K	0000950170-23-011138
9	net income	us-gaap:NetIncomeLoss	-\$8.6M	2025-12-31	2026-03-04	10-K	0001178253-26-000007
10	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$5.3M	2025-12-31	2026-03-04	10-K	0001178253-26-000007
11	assets	us-gaap:Assets	\$59.0M	2025-12-31	2026-03-04	10-K	0001178253-26-000007
12	assets	us-gaap:Assets	\$90.6M	2024-12-31	2026-03-04	10-K	0001178253-26-000007
13	current assets	us-gaap:AssetsCurrent	\$40.4M	2025-12-31	2026-03-04	10-K	0001178253-26-000007
14	current liabilities	us-gaap:LiabilitiesCurrent	\$5.7M	2025-12-31	2026-03-04	10-K	0001178253-26-000007
15	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$385.1M	2025-12-31	2026-03-04	10-K	0001178253-26-000007
16	operating income	us-gaap:OperatingIncomeLoss	-\$16.1M	2025-12-31	2026-03-04	10-K	0001178253-26-000007
17	book equity	us-gaap:StockholdersEquity	\$49.4M	2025-12-31	2026-03-04	10-K	0001178253-26-000007
18	liabilities	us-gaap:Liabilities	\$9.7M	2025-12-31	2026-03-04	10-K	0001178253-26-000007
19	depreciation amortization	us-gaap:Depreciation	\$200,000	2021-12-31	2022-03-29	10-K	0001564590-22-012199
20	operating income	us-gaap:OperatingIncomeLoss	\$72.7M	2023-12-31	2025-03-12	10-K	0000950170-25-038044
21	interest expense	us-gaap:InterestExpense	\$3.1M	2023-12-31	2024-03-28	10-K	0000950170-24-038046
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$20.6M	2025-12-31	2026-03-04	10-K	0001178253-26-000007
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$3.7M	2024-12-31	2026-03-04	10-K	0001178253-26-000007
24	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$140.1M	2023-12-31	2025-03-12	10-K	0000950170-25-038044
25	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$5.1M	2022-12-31	2024-03-28	10-K	0000950170-24-038046
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$54.6M	2021-12-31	2023-03-31	10-K	0000950170-23-011138
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$0	2021-12-31	2022-03-29	10-K	0001564590-22-012199
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$49.4M	2020-12-31	2022-03-29	10-K	0001564590-22-012199
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$4,000	2020-12-31	2022-03-29	10-K	0001564590-22-012199
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$38.1M	2019-12-31	2021-03-29	10-K	0001564590-21-015962
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$0	2019-12-31	2021-03-29	10-K	0001564590-21-015962
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$28.3M	2018-12-31	2020-03-11	10-K	0001564590-20-009875
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$565,000	2018-12-31	2020-03-11	10-K	0001564590-20-009875
34	current assets	us-gaap:AssetsCurrent	\$109.4M	2021-12-31	2023-03-31	10-K	0000950170-23-011138
35	current liabilities	us-gaap:LiabilitiesCurrent	\$13.6M	2021-12-31	2023-03-31	10-K	0000950170-23-011138
36	current assets	us-gaap:AssetsCurrent	\$98.2M	2020-12-31	2022-03-29	10-K	0001564590-22-012199
37	current liabilities	us-gaap:LiabilitiesCurrent	\$26.4M	2020-12-31	2022-03-29	10-K	0001564590-22-012199
38	assets	us-gaap:Assets	\$128.4M	2023-12-31	2025-03-12	10-K	0000950170-25-038044
39	assets	us-gaap:Assets	\$87.8M	2022-12-31	2024-03-28	10-K	0000950170-24-038046
40	shares outstanding	dei:EntityCommonStockSharesOutstanding	44,663,832	2026-03-01	2026-03-04	10-K	0001178253-26-000007
41	shares outstanding	dei:EntityCommonStockSharesOutstanding	38,981,064	2025-03-01	2025-03-12	10-K	0000950170-25-038044